Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Dec 1;32(34):3801-9.
doi: 10.1200/JCO.2014.57.5548. Epub 2014 Nov 3.

Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233

Raymond H Mak  1 , Daniel Hunt  2 , William U Shipley  2 , Jason A Efstathiou  2 , William J Tester  2 , Michael P Hagan  2 , Donald S Kaufman  2 , Niall M Heney  2 , Anthony L Zietman  2
Affiliations

Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233

Raymond H Mak et al. J Clin Oncol. .

Erratum in

  • Errata.
    [No authors listed] [No authors listed] J Clin Oncol. 2015 Mar 1;33(7):814. doi: 10.1200/JCO.2015.61.1491. J Clin Oncol. 2015. PMID: 25721580 Free PMC article. No abstract available.

Abstract

Purpose: Multiple prospective Radiation Therapy Oncology Group (RTOG) protocols have evaluated bladder-preserving combined-modality therapy (CMT) for muscle-invasive bladder cancer (MIBC), reserving cystectomy for salvage treatment. We performed a pooled analysis of long-term outcomes in patients with MIBC enrolled across multiple studies.

Patients and methods: Four hundred sixty-eight patients with MIBC were enrolled onto six RTOG bladder-preservation studies, including five phase II studies (RTOG 8802, 9506, 9706, 9906, and 0233) and one phase III study (RTOG 8903). Overall survival (OS) was estimated using the Kaplan-Meier method, and disease-specific survival (DSS), muscle-invasive and non-muscle-invasive local failure (LF), and distant metastasis (DM) were estimated by the cumulative incidence method.

Results: The median age of patients was 66 years (range, 34 to 93 years), and clinical T stage was T2 in 61%, T3 in 35%, and T4a in 4% of patients. Complete response to CMT was documented in 69% of patients. With a median follow-up of 4.3 years among all patients and 7.8 years among survivors (n = 205), the 5- and 10-year OS rates were 57% and 36%, respectively, and the 5- and 10-year DSS rates were 71% and 65%, respectively. The 5- and 10-year estimates of muscle-invasive LF, non-muscle-invasive LF, and DM were 13% and 14%, 31% and 36%, and 31% and 35%, respectively.

Conclusion: This pooled analysis of multicenter, prospective RTOG bladder-preserving CMT protocols demonstrates long-term DSS comparable to modern immediate cystectomy studies, for patients with similarly staged MIBC. Given the low incidence of late recurrences with long-term follow-up, CMT can be considered as an alternative to radical cystectomy, especially in elderly patients not well suited for surgery.

Trial registration: ClinicalTrials.gov NCT00003930 NCT00055601.

PubMed Disclaimer

Conflict of interest statement

Authors' disclosures of potential conflicts of interest are found in the article online at www.jco.org. Author contributions are found at the end of this article.

Figures

Fig 1.
Fig 1.
CONSORT diagram of Radiation Therapy Oncology Group protocol 8903. MCV, methotrexate, cisplatin, and vinblastine; TURBT, transurethral resection of bladder tumor. Data adapted.
Fig 2.
Fig 2.
CONSORT diagram of Radiation Therapy Oncology Group protocol 0233. MCV, methotrexate, cisplatin, and vinblastine; TURBT, transurethral resection of bladder tumor. Data adapted.
Fig 3.
Fig 3.
(A) Overall survival in all patients. (B) Disease-specific survival (DSS) and bladder-intact disease-free survival (BIDFS) in all patients. (C) Overall survival in patients with clinical T2 versus T3/4 disease. (D) DSS in patients with clinical T2 versus T3/4 disease. (E) DSS in patients with a complete response after combined-modality therapy compared with patients who were nonresponders. (F) DSS in patients age 75 years or older versus patients younger than age 75 years.
See this image and copyright information in PMC

Comment in

References

    1. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients. J Clin Oncol. 2001;19:666–675. - PubMed
    1. Dalbagni G, Genega E, Hashibe M, et al. Cystectomy for bladder cancer: A contemporary series. J Urol. 2001;165:1111–1116. - PubMed
    1. Zehnder P, Studer UE, Skinner EC, et al. Super extended versus extended pelvic lymph node dissection in patients undergoing radical cystectomy for bladder cancer: A comparative study. J Urol. 2011;186:1261–1268. - PubMed
    1. Madersbacher S, Hochreiter W, Burkhard F, et al. Radical cystectomy for bladder cancer today: A homogeneous series without neoadjuvant therapy. J Clin Oncol. 2003;21:690–696. - PubMed
    1. Hautmann RE, Gschwend JE, de Petriconi RC, et al. Cystectomy for transitional cell carcinoma of the bladder: Results of a surgery only series in the neobladder era. J Urol. 2006;176:486–492. - PubMed

Publication types

MeSH terms

Associated data